House panel presses for permanent cap on anti-cancer drug trade margins
A parliamentary committee rejected the government’s response and urged urgent legal changes to cap trade margins on life-saving medicines. Its proposed 30% cap covers 42 non-scheduled anti-cancer drugs across 526 brands, with potential implications for pharmacy pricing and distributor margins.
A parliamentary panel urged urgent legal amendments to permanently cap trade margins on life-saving drugs, especially anti-cancer medicines. It also sought tighter oversight of non-scheduled medicines and trade generics, potentially affecting pricing, margins and distribution across India’s pharmaceutical retail market.
Why this matters
No related recent Department of Pharmaceuticals signals were provided. The committee's push puts pharmacy pricing and distributor margins under renewed regulatory scrutiny.
Retail-company signals are accelerating, up +388367% QoQ.